News stories about Abbott Laboratories (NYSE:ABT) have been trending positive this week, according to Accern Sentiment. The research firm scores the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Abbott Laboratories earned a media sentiment score of 0.39 on Accern’s scale. Accern also gave news articles about the healthcare product maker an impact score of 45.8236920454195 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.

These are some of the media stories that may have impacted Accern Sentiment’s scoring:

Several equities research analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Abbott Laboratories from a “buy” rating to a “hold” rating in a research report on Monday, August 6th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $70.00 price target on shares of Abbott Laboratories in a research report on Thursday, July 19th. Stifel Nicolaus upped their price target on shares of Abbott Laboratories from $71.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, July 19th. Finally, Sanford C. Bernstein assumed coverage on shares of Abbott Laboratories in a research report on Wednesday, June 27th. They issued an “outperform” rating and a $73.00 price target for the company. Four investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. Abbott Laboratories currently has an average rating of “Buy” and an average target price of $69.88.

NYSE ABT opened at $66.21 on Friday. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.58 and a quick ratio of 1.16. The company has a market cap of $115.79 billion, a P/E ratio of 26.48, a PEG ratio of 1.85 and a beta of 1.48. Abbott Laboratories has a 52 week low of $51.29 and a 52 week high of $67.36.

Abbott Laboratories (NYSE:ABT) last posted its quarterly earnings data on Wednesday, July 18th. The healthcare product maker reported $0.73 EPS for the quarter, topping the consensus estimate of $0.71 by $0.02. Abbott Laboratories had a net margin of 3.13% and a return on equity of 15.30%. The firm had revenue of $7.77 billion during the quarter, compared to analyst estimates of $7.71 billion. During the same quarter in the previous year, the business posted $0.62 EPS. Abbott Laboratories’s revenue was up 17.0% on a year-over-year basis. research analysts forecast that Abbott Laboratories will post 2.88 earnings per share for the current fiscal year.

In other Abbott Laboratories news, EVP Brian J. Blaser sold 15,100 shares of the company’s stock in a transaction that occurred on Tuesday, July 24th. The shares were sold at an average price of $63.96, for a total transaction of $965,796.00. Following the transaction, the executive vice president now owns 151,718 shares in the company, valued at approximately $9,703,883.28. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Andrew H. Lane sold 9,097 shares of the company’s stock in a transaction that occurred on Wednesday, August 29th. The shares were sold at an average price of $67.11, for a total transaction of $610,499.67. Following the transaction, the insider now owns 35,576 shares in the company, valued at approximately $2,387,505.36. The disclosure for this sale can be found here. Insiders have sold a total of 90,389 shares of company stock worth $5,995,012 in the last 90 days. 0.74% of the stock is currently owned by company insiders.

About Abbott Laboratories

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company's Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptoms; gynecological disorders; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière's disease and vestibular vertigo; pain, fever, and inflammation; migraines; and anti-infective clarithromycin, as well as provides influenza vaccine and products that regulate physiological rhythm of the colon.

Read More: Marijuana Stocks Investing Considerations

Insider Buying and Selling by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.